Trend analysis of cancer mortality and years of life lost in the South of Iran 2004-2019. Joinpoint regression analysis

2004-2019年伊朗南部癌症死亡率和预期寿命损失年数的趋势分析。连接点回归分析

阅读:1

Abstract

BACKGROUND: Cancer is the second leading cause of death globally and is a significant financial burden on public health systems. This study aimed to investigate cancer mortality trends and years of life lost (YLL) in Fars province. METHOD: The data on the total number of deaths caused by cancer in Fars Province was collected from the Electronic Population-Based Death Registration System (EDRS). Various statistics such as crude and age-standardized mortality rates, YLL, and YLL rates were computed. To analyze the trend, the JoinPoint Regression method was utilized. RESULTS: Over a period of 16 years (2004–2019), there were 31,669 recorded deaths in Fars province. Of these, 59.4% (18806 cases) were male. The trend in age-standardized mortality rate (ASMR) rose for both males and females. The annual percent change (APC) was 1.3 (0.6 to 2.1, P for trend = 0.002) for males and 1.8 (0.8 to 2.9, P for trend = 0.001) for females. During the 16-year study period, the total YLL was 247,035 (7.8 per 1000 people) in males and 202,037 (6.6 per 1000 people) in females. The highest number of YLL in males due to cancer was caused by leukemia and lymphoma (13.3%), stomach (13.1%), and lung (11.4%). In females, the highest number of YLL due to cancer was caused by breast (16.4%), leukemia and lymphoma (11.4%), and stomach (9.9%). Based on the join point regression analysis, the rate of YLL due to premature mortality increased during the 16-year trend: APC was 2.3% (95% CI 1.8 to 2.8, p<0.001) for males and 3.5% (95% CI 2.7 to 4.4, p<0.001) for females. CONCLUSION: The crude, standardized mortality rates and years of life lost (YLL) due to cancer have been increasing in both males and females. As a result, public health programs and research funding should be more explicitly directed towards preventing premature mortality. YLL can be a useful measure for easy comparison of different cancers by policymakers and health practitioners. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-025-15217-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。